Vaccines are the dominating segment. Their leadership is driven by the increasing incidence of avian diseases like Newcastle disease and avian influenza, as well as a global shift toward preventive health management over therapeutic treatment to reduce reliance on antibiotics.
Feed additives are surging due to the global movement toward antibiotic-free poultry production. Natural solutions such as probiotics, enzymes, and prebiotics are being used to improve gut health and nutrient absorption, catering to consumer demand for residue-free meat and eggs.
Strict regulations, particularly in Europe and North America, have banned the use of antibiotics as growth promoters. This has forced pharmaceutical companies to pivot their R&D toward sustainable alternatives like immune modulators, plant-based antimicrobials, and novel vaccination platforms.
The integration of precision poultry farming is creating a coalescence between pharmaceuticals and digital technology. Innovations include AI-driven feed additive optimization, real-time disease surveillance, and automated vaccination systems, which allow for more holistic and efficient flock health management.
Asia-Pacific is predicted to be the fastest-growing market. This growth is fueled by rising urban populations, increased discretionary income, and massive poultry consumption in countries like China and India, alongside government efforts to improve biosecurity.
The industry faces significant hurdles, including high R&D costs, lengthy regulatory approval timelines, and fluctuating prices of raw materials. Additionally, supply chain vulnerabilities during disease outbreaks can hinder the effective distribution of vaccines.
In early 2024, Zoetis expanded its portfolio with a recombinant vector vaccine for multi-disease protection. Simultaneously, Merck Animal Health announced a USD 150 million investment in new R&D laboratories in Germany specifically to innovate precision parasiticides for coccidiosis.
Frequent outbreaks create high pressure on pharmaceutical companies to ramp up emergency vaccine production and maintain supply chain resilience. These risks drive producers to adopt comprehensive preventive medicine programs, ensuring steady demand for broad-spectrum therapeutics and vaccines.
Key market players include Zoetis Inc., Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, Ceva Santé Animale, Phibro Animal Health Corporation, HIPRA, Virbac SA, Biovac, and Huvepharma.
